Sanara Medtech Inc (SMTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sanara Medtech Inc (SMTI) has a cash flow conversion efficiency ratio of 0.665x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.95 Million) by net assets ($5.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SMTI defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Sanara Medtech Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Sanara Medtech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sanara Medtech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanara Medtech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BYC Co. Ltd
KO:001460
|
0.030x |
|
POLARIS RENEWABLE ENERGY
F:N4T
|
N/A |
|
Daios Plastics S.A.
AT:DAIOS
|
N/A |
|
GEVORKYAN as
PR:GEV
|
N/A |
|
Westwood Holdings Group Inc
NYSE:WHG
|
-0.020x |
|
Zhong Yang Technology Co Ltd
TW:6668
|
-0.018x |
|
Mendelson Infrastructures and Industries Ltd
TA:MNIN
|
0.061x |
|
Shandong Molong Petroleum Machinery Company Limited
F:PXI
|
0.088x |
Annual Cash Flow Conversion Efficiency for Sanara Medtech Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Sanara Medtech Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Sanara Medtech Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.93 Million | $6.79 Million | 1.145x | +187346.65% |
| 2024-12-31 | $38.91 Million | $-23.78K | -0.001x | +99.16% |
| 2023-12-31 | $44.59 Million | $-3.25 Million | -0.073x | +45.33% |
| 2022-12-31 | $41.72 Million | $-5.55 Million | -0.133x | +16.61% |
| 2021-12-31 | $30.15 Million | $-4.81 Million | -0.160x | +76.89% |
| 2020-12-31 | $5.84 Million | $-4.03 Million | -0.691x | -103.74% |
| 2019-12-31 | $6.39 Million | $-2.17 Million | -0.339x | -236.05% |
| 2018-12-31 | $1.11 Million | $277.14K | 0.249x | +118.27% |
| 2017-12-31 | $102.54K | $-139.86K | -1.364x | -41.01% |
| 2016-12-31 | $-423.07K | $409.25K | -0.967x | -202.23% |
| 2015-12-31 | $-1.27 Million | $-1.20 Million | 0.946x | -53.70% |
| 2014-12-31 | $-825.40K | $-1.69 Million | 2.043x | +176.87% |
| 2013-12-31 | $-2.47 Million | $-1.82 Million | 0.738x | +129.08% |
| 2012-12-31 | $-3.81 Million | $-1.23 Million | 0.322x | +261.94% |
| 2011-12-31 | $-3.86 Million | $-343.60K | 0.089x | +117.11% |
| 2010-12-31 | $2.87 Million | $-1.49 Million | -0.520x | +7.01% |
| 2009-12-31 | $2.31 Million | $-1.30 Million | -0.560x | -116.99% |
| 2008-12-31 | $-321.26K | $-1.06 Million | 3.295x | +1468.87% |
| 2007-12-31 | $-1.81 Million | $-380.90K | 0.210x | -33.10% |
| 2006-12-31 | $-1.27 Million | $-398.97K | 0.314x | -67.45% |
| 2005-12-31 | $-647.47K | $-624.45K | 0.964x | +107.24% |
| 2004-12-31 | $41.20K | $-548.46K | -13.313x | -3955.33% |
| 2001-12-31 | $-2.10 Million | $-723.86K | 0.345x | -16.37% |
| 2000-12-31 | $-1.38 Million | $-569.36K | 0.413x | -75.18% |
| 1999-12-31 | $-377.38K | $-627.86K | 1.664x | -- |
About Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and seco… Read more